Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sandostatin and the Hammersmith experience.

D Wynick1, S R Bloom

  • 1Department of Medicine, Hammersmith Hospital, London, UK.

Digestion
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Galanin acts as a trophic factor to the central and peripheral nervous systems.

Experientia supplementum (2012)·2011
Same author

Novel mRNA isoforms of the sodium channels Na(v)1.2, Na(v)1.3 and Na(v)1.7 encode predicted two-domain, truncated proteins.

Neuroscience·2008
Same author

Galanin acts as a trophic factor to the central and peripheral nervous systems.

Cellular and molecular life sciences : CMLS·2008
Same author

Feeding behaviour in galanin knockout mice supports a role of galanin in fat intake and preference.

Journal of neuroendocrinology·2007
Same author

Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury.

Neuropeptides·2005
Same author

Obesity and endocrine dysfunction in mice with deletions of both neuropeptide Y and galanin.

Molecular and cellular biology·2004

Sandostatin (octreotide) effectively reduced tumor secretions and improved symptoms in metastatic pancreatic cancer patients. However, patients eventually developed resistance, leading to treatment failure and death.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Metastatic pancreatic tumors often present challenges in management.
  • Hormonal secretions from tumors can exacerbate clinical symptoms.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of Sandostatin (octreotide) in patients with metastatic pancreatic tumors.
  • To assess the impact of Sandostatin on tumor secretions and clinical symptoms.

Main Methods:

  • Ten patients with metastatic pancreatic tumors received Sandostatin subcutaneously.
  • Dosage was escalated from 50 mcg t.i.d. to 500 mcg t.i.d. over 6-12 months.
  • Treatment duration was up to 5 years, with monitoring of biochemical and clinical parameters.

Main Results:

Related Experiment Videos

  • Seven out of ten patients showed significant reduction in tumor secretions (nearly 60%) and clinical improvement.
  • All patients eventually developed resistance to Sandostatin within 5-6 months, leading to worsening symptoms.
  • Side effects were minimal, with no observed steatorrhoea or gallstone development.

Conclusions:

  • Sandostatin demonstrates significant short-term efficacy in managing metastatic pancreatic tumors.
  • Long-term treatment is limited by the eventual development of therapeutic resistance.
  • Further research is needed to overcome treatment resistance in these patients.